Coutant, David E.
Eli Lilly (United States)
4 papers on CoChatORCID 0000-0002-6291-5623
Most cited papers
- Verified
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 52
- Verified
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus
Aronson, R., Biester, T., Leohr, J., Pollom, R., Linnebjerg, H., LaBell, E. S., Zhang, Q., Coutant, D. E., & Danne, T. (2023) · Diabetes, Obesity and Metabolism
Diabetes Management and ResearchDiabetes Treatment and Management
Cited by 14
- Verified
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight
Ma, X., Li, Y. G., Raha, S., Sperry, D. C., Coutant, D. E., & Bhattachar, S. (2026) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 13
- Verified
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development
Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free